Metformin extended-release versus immediate-release:An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes

Aggarwal, Naresh, Singla, Anuj, Mathieu, Chantal, Montanya, Eduard, Pfeiffer, Andreas F.H., Johnsson, Eva, Zhao, June, Iqbal, Nayyar and Bailey, Clifford (2017). Metformin extended-release versus immediate-release:An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism, Early ,

Abstract

This international, randomized, double-blind trial (NCT01864174) compared the efficacy and safety of metformin extended-release (XR) and immediate-release (IR) in patients with type 2 diabetes. After a 4-week placebo lead-in, pharmacotherapy-naïve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once-daily metformin XR 2000mg or twice-daily metformin IR 1000mg for 24weeks. The primary endpoint was change in HbA1c after 24weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24weeks. Overall, 539 patients were randomized (metformin XR, N=268; metformin IR, N=271). Adjusted mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c <7.0% after 24weeks were similar for XR and IR: -0.93% vs -0.96%; -21.1 vs -20.6mg/dL (-1.2 vs -1.1mmol/L); -24.7 vs -27.1mg/dL (-1.4 vs -1.5mmol/L); and 70.9% vs 72.0%, respectively. Adverse events were similar between groups and consistent with previous studies. Overall, metformin XR demonstrated efficacy and safety similar to that of metformin IR over 24weeks, with the advantage of once-daily dosing.

Publication DOI: https://doi.org/10.1111/dom.13104
Divisions: Life & Health Sciences > Biosciences
Additional Information: © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Funding: AstraZeneca.
Uncontrolled Keywords: Glycated haemoglobin,Metformin extended-release,Once-daily dosing,Randomized clinical trial,Type 2 diabetes,Internal Medicine,Endocrinology, Diabetes and Metabolism,Endocrinology
Full Text Link: http://onlineli ... .13104/abstract
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Date: 2017-10-02
Authors: Aggarwal, Naresh
Singla, Anuj
Mathieu, Chantal
Montanya, Eduard
Pfeiffer, Andreas F.H.
Johnsson, Eva
Zhao, June
Iqbal, Nayyar
Bailey, Clifford ( 0000-0002-6998-6811)

Download

Export / Share Citation


Statistics

Additional statistics for this record